Boston Therapeutics is a pharmaceutical company focused on the development, manufacturing and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in diabetes.
The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules. BTI-320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. BTI-320 inhibits the enzymes that release glucose from complex carbohydrates in foods during digestion, reducing the amount of available glucose absorbed through the intestine.
IPOXYN is a glyco-protein based therapeutic agent using proprietary processes and patented technology. IPOXYN is an anti-necrosis drug that consists of a stabilized glycoprotein composition containing oxygen-rechargeable iron, targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support.
OXYFEX can serve as the only available oxygen delivery mechanism for animals suffering ischemia or traumatic and surgical blood loss events.

Show more
TypePublic
HQLawrence, US
Founded2009
Size (employees)7 (est)
Websitebostonti.com
Boston Therapeutics was founded in 2009 and is headquartered in Lawrence, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Boston Therapeutics Office Locations

Boston Therapeutics has an office in Lawrence
Lawrence, (HQ)
354 Merrimack St
Show all (1)
Report incorrect company information

Boston Therapeutics Financials and Metrics

Boston Therapeutics Revenue

Boston Therapeutics's revenue was reported to be $29.36 k in FY, 2017
USD

Revenue (Q3, 2018)

7.8k

Net income (Q3, 2018)

764.6k

EBIT (Q3, 2018)

(354.5k)

Market capitalization (8-Oct-2018)

3.9m

Cash (30-Sep-2018)

311.0k
Boston Therapeutics's current market capitalization is $3.9 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Revenue

323.4k98.9k98.9k29.4k

Revenue growth, %

0%

Cost of goods sold

278.2k240.5k94.1k

Gross profit

45.2k(141.5k)4.7k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

217.5k43.8k21.4k121.5k38.9k4.6k12.3k16.3k11.7k4.5k5.2k4.4k9.2k8.2k7.8k

Cost of goods sold

118.5k54.6k22.0k82.1k66.8k50.1k15.9k8.7k17.2k8.9k7.2k17.8k

Gross profit

99.0k(10.7k)(595.0)39.4k(27.9k)(45.5k)(3.6k)7.6k(5.5k)(4.5k)(1.9k)(13.4k)

Gross profit Margin, %

46%(24%)(3%)32%(72%)(988%)(29%)47%(47%)(99%)(37%)(304%)
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Cash

3.4m41.0k687.2k137.3k

Accounts Receivable

99.8k5.0k588.0

Inventories

110.6k109.8k55.1k38.5k

Current Assets

3.8m229.1k830.0k390.9k
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Net Income

(4.6m)(2.5m)(3.7m)(1.6m)

Depreciation and Amortization

67.1k71.0k70.4k67.0k

Inventories

(93.8k)(24.2k)54.6k3.6k

Accounts Payable

(123.2k)225.1k213.3k(20.2k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(2.3m)(1.6m)(2.8m)(3.9m)(1.4m)(1.9m)(419.3k)(787.0k)(5.4m)(708.1k)(2.7m)(2.9m)(2.1m)

Depreciation and Amortization

49.7k17.5k35.4k53.2k35.6k53.3k17.7k35.4k53.1k40.4k80.6k120.6k

Inventories

(173.2k)13.1k(62.3k)(67.0k)45.2k(59.2k)5.8k6.9k9.3k1.7k3.6k4.9k

Accounts Payable

(179.4k)(99.2k)(75.4k)115.7k270.6k479.3k(21.1k)(52.3k)180.4k349.7k63.1k18.0k61.0k
USDY, 2018

Financial Leverage

-1.6 x
Show all financial metrics
Report incorrect company information

Boston Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Boston Therapeutics News and Updates

Boston Therapeutics Announces Initiation of Sales of Sugardown® in Asia

LAWRENCE, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. (the “Company” or “BTI”) (OTCQB: BTHE), an innovator in the design, development and commercialization of novel therapeutics as an adjunct therapy for diabetes, launches an initial sale of product in Myanmar and test marke…

Boston Therapeutics to launch social commerce channel for Sugardown® in China

For product distribution via a multi-purpose super-app that fuses communications with commerce For product distribution via a multi-purpose super-app that fuses communications with commerce
Report incorrect company information

Boston Therapeutics Company Life and Culture

Report incorrect company information

Boston Therapeutics Frequently Asked Questions

  • When was Boston Therapeutics founded?

    Boston Therapeutics was founded in 2009.

  • How many employees does Boston Therapeutics have?

    Boston Therapeutics has 7 employees.

  • What is Boston Therapeutics revenue?

    Latest Boston Therapeutics annual revenue is $29.4 k.

  • What is Boston Therapeutics revenue per employee?

    Latest Boston Therapeutics revenue per employee is $4.2 k.

  • Who are Boston Therapeutics competitors?

    Competitors of Boston Therapeutics include Inversago Pharma, Laboratorios Farmaceuticos ROVI and Diasome.

  • Where is Boston Therapeutics headquarters?

    Boston Therapeutics headquarters is located at 354 Merrimack St, Lawrence.

  • Where are Boston Therapeutics offices?

    Boston Therapeutics has an office in Lawrence.

  • How many offices does Boston Therapeutics have?

    Boston Therapeutics has 1 office.